Aurobindo Pharma to bring Azithromycin tablets to market
11 July 2018 | News
The approved product is a generic equivalent of Pfizer Inc's Zithromax tablet.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azithromycin tablets.
These tablets will be used for the treatment of patients with mild to moderate infections, in the US market.
Hyderabad-based company said that the product will be launched in July 2018.
The approval has been granted in the strengths of 250 mg and 500 mg, and the product will be launched this month.
The approved product is a generic equivalent of Pfizer Inc's Zithromax tablet.
Quoting IQVIA sales data, the company said, the approved product has an estimated market size of USD 132 million for the 12 months ending May 2018.
This is the 146th ANDA (including 19 tentative approvals) to be approved out of the Unit VII formulation facility in Hyderabad, used for manufacturing oral products.
